Cargando…
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade. Evidence for WNT/β-catenin signaling-mediated immune evasion is found in a subset of cancers including mel...
Autores principales: | Waaler, Jo, Mygland, Line, Tveita, Anders, Strand, Martin Frank, Solberg, Nina Therese, Olsen, Petter Angell, Aizenshtadt, Aleksandra, Fauskanger, Marte, Lund, Kaja, Brinch, Shoshy Alam, Lycke, Max, Dybing, Elisabeth, Nygaard, Vegard, Bøe, Sigurd Læines, Heintz, Karen-Marie, Hovig, Eivind, Hammarström, Clara, Corthay, Alexandre, Krauss, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181813/ https://www.ncbi.nlm.nih.gov/pubmed/32332858 http://dx.doi.org/10.1038/s42003-020-0916-2 |
Ejemplares similares
-
Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines
por: Mygland, Line, et al.
Publicado: (2021) -
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models
por: Brinch, Shoshy A., et al.
Publicado: (2022) -
Preclinical Lead
Optimization of a 1,2,4-Triazole
Based Tankyrase Inhibitor
por: Waaler, Jo, et al.
Publicado: (2020) -
Development of
a 1,2,4-Triazole-Based Lead Tankyrase
Inhibitor: Part II
por: Leenders, Ruben G. G., et al.
Publicado: (2021) -
Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses
por: Nygaard, Vegard, et al.
Publicado: (2016)